| [1] |
Bennett JM：MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes[J].Am J Hematol,2008,83(11):858-61.
|
| [2] |
Nimer SD.Myelodysplastic syndromes[J].Blood,2008,111(10):4841-51.
|
| [3] |
Blum W.How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes[J].Hematology Am Soc Hematol Educ Program,2010,2010:314-21.
|
| [4] |
Gao Y, Ping BH, Zhou SY.Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literarure[J].Nan Fang Yi Ke Da Xue Xue Bao,2012,32(2):280-2.[高雅,平宝红,周淑 芸.地西他滨治疗老年骨髓增生异常综合征1例并文献复习[J].南方医科大学学报, 2012,32(2):280-2.]
|
| [5] |
Cheson BD, Bennett JM, Kantarjian H, et al.Report of an international working group to standardize response criteria for myelodysplastic syndromes[J].Blood,2000,96(12):3671-4.
|
| [6] |
Lübbert M, Suciu S, Baila L, et al.Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].J Clin Oncol,2011,29(15):1987-96.
|
| [7] |
Kantarjian HM, O′Brien S, Huang X, et al.Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience[J].Cancer,2007,109(6):1133-7.
|
| [8] |
Kantarjian H, Issa JP, Rosenfeld CS, et al.Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study[J].Cancer,2006,106(8):1794-803.
|
| [9] |
Miranda TB, Jones PA.DNA methylation: the nuts and bolts of repression[J].J Cell Physiol,2007,213(2):384-90.
|
| [10] |
Jones PA, Baylin SB.The fundamental role of epigenetic events in cancer[J].Nat Rev Genet,2002,3 (6):415-28.
|
| [11] |
Leone G, Voso MT, Teofili L, et al.Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS[J].Clin Immunol,2003,109(1):89-102.
|
| [12] |
Jiang Y, Dunbar A, Gondek LP, et al.Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J].Blood,2009,113(6):1315-25.
|
| [13] |
Shen L, Kantarjian H, Saba H, et al. (2005). CpG island methylation is a poor prognostic factors in myelodysplastic syndrome patients and is reversed by decitabine therapy results of a phase III randomized study[J].Blood,2005,106(11pt1):790.
|
| [14] |
Bhalla KN.Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies[J].J Clin Oncol,2005,23(17):3971-93.
|
| [15] |
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109(1):52-7.
|
| [16] |
Rius M, Stresemann C, Keller D, et al.Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation[J].Mol Cancer Ther,2009,8(1):225-31.
|
下载:
